PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23354417-7 2013 When the phosphorylation of p38 was inhibited by SB203580 (a p38 inhibitor), the S100A9-induced cell invasion was reversed; when the phosphorylation of ERK1/2 was inhibited by PD98059 (an ERK1/2 inhibitor), the S100A9-induced cell proliferation was reversed. SB 203580 49-57 mitogen-activated protein kinase 3 Homo sapiens 152-158 23577625-9 2013 In addition, a p38 inhibitor (SB203580) improved MMP-1 up-regulation through the stimulation of ERK1/2. SB 203580 30-38 mitogen-activated protein kinase 3 Homo sapiens 96-102 23354417-7 2013 When the phosphorylation of p38 was inhibited by SB203580 (a p38 inhibitor), the S100A9-induced cell invasion was reversed; when the phosphorylation of ERK1/2 was inhibited by PD98059 (an ERK1/2 inhibitor), the S100A9-induced cell proliferation was reversed. SB 203580 49-57 mitogen-activated protein kinase 3 Homo sapiens 188-194 24251013-4 2013 Pharmacological inhibition was performed by SB203580, PD980559 and SP6000125 for P38MAPK, ERK1/2 and JNK activity, respectively. SB 203580 44-52 mitogen-activated protein kinase 3 Homo sapiens 90-96 23085266-10 2013 SB203580 and UO126, inhibitors of p38MAPK and ERK1/2-pathway, respectively, inhibited phosphorylation of p47phox on Ser345. SB 203580 0-8 mitogen-activated protein kinase 3 Homo sapiens 46-52 23363008-7 2013 The employment of protein kinase inhibitors LY294002, SB203580, SP600125, and U0126 revealed that PI3K/Akt signaling pathway interplayed with MAPK signaling pathways. SB 203580 54-62 mitogen-activated protein kinase 3 Homo sapiens 142-146 22739240-9 2012 The analyses of signal transduction pathways that may play a role in the regulation of gene expression by H(2)O(2 )using several specific inhibitors showed that U0126, an inhibitor of ERK1/2 upstream kinase MEK1/2, blocked both H(2)O(2)-induced inhibition of SP-A and SP-B gene expression, whereas SB203580, an inhibitor of p38 MAPK, partially blocked H(2)O(2)-mediated inhibition of SP-A gene expression but not SP-B expression. SB 203580 298-306 mitogen-activated protein kinase 3 Homo sapiens 184-190 23468994-6 2013 Inhibition of extracellular signal-regulated kinase 1/2 (ERK1/2) activation with PD98059 and p38 mitogen-activated protein kinase activity by SB203580 resulted in suppression of TGF-beta-induced TIMP-3 expression, indicating that ERK1/2 and p38 MAPK mediate the effect of TGF-beta on TIMP-3 expression. SB 203580 142-150 mitogen-activated protein kinase 3 Homo sapiens 57-63 23468994-6 2013 Inhibition of extracellular signal-regulated kinase 1/2 (ERK1/2) activation with PD98059 and p38 mitogen-activated protein kinase activity by SB203580 resulted in suppression of TGF-beta-induced TIMP-3 expression, indicating that ERK1/2 and p38 MAPK mediate the effect of TGF-beta on TIMP-3 expression. SB 203580 142-150 mitogen-activated protein kinase 3 Homo sapiens 230-236 22138297-5 2012 FA was also found to trigger an early phosphorylation of p38 and extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinases (MAPKs) in BEAS-2B cells, whose inhibition by ERK and p38 MAPK chemical inhibitors (U0126 and SB203580, respectively) counteracted FA-mediated induction of IL-11. SB 203580 240-248 mitogen-activated protein kinase 3 Homo sapiens 104-107 22138297-5 2012 FA was also found to trigger an early phosphorylation of p38 and extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinases (MAPKs) in BEAS-2B cells, whose inhibition by ERK and p38 MAPK chemical inhibitors (U0126 and SB203580, respectively) counteracted FA-mediated induction of IL-11. SB 203580 240-248 mitogen-activated protein kinase 3 Homo sapiens 147-151 22138297-8 2012 We finally showed using SB203580 and RO-31-8220 that phosphorylation of CREB and CREB-promoter activity induced by FA are under the control of both p38 MAPK and PKC. SB 203580 24-32 mitogen-activated protein kinase 3 Homo sapiens 152-156 22799384-6 2012 In addition, ERK1/2 and p38 MAPK were shown to play a crucial role in mediating EGF-induced NF-kappaB translocation and phosphorylation of IkappaBalpha when treated with the MAPK inhibitors, PD98059 and SB203580, which resulted in increased MMP-12 expression. SB 203580 203-211 mitogen-activated protein kinase 3 Homo sapiens 13-19 22799384-6 2012 In addition, ERK1/2 and p38 MAPK were shown to play a crucial role in mediating EGF-induced NF-kappaB translocation and phosphorylation of IkappaBalpha when treated with the MAPK inhibitors, PD98059 and SB203580, which resulted in increased MMP-12 expression. SB 203580 203-211 mitogen-activated protein kinase 3 Homo sapiens 28-32 23149874-8 2012 The further study indicated that hexamethonium, PD98059, and SB203580 significantly inhibited ERK1/2 and p38 MAPK phosphorylation. SB 203580 61-69 mitogen-activated protein kinase 3 Homo sapiens 94-100 22942680-5 2012 Consistently, ODN MT01 induced up-regulation of osteocalcin, alkaline phosphatase (ALP) and type I collagen, which was inhibited by pre-treatment with the ERK1/2 inhibitor U0126 and the p38 inhibitor SB203580. SB 203580 200-208 mitogen-activated protein kinase 3 Homo sapiens 155-161 21647617-7 2011 Furthermore, downregulation of AQP1 expression by LPS was blocked by SB203580, SP600125, and PD98059, which are inhibitors of p38, JNK, and ERK1/2, respectively. SB 203580 69-77 mitogen-activated protein kinase 3 Homo sapiens 140-146 21574189-5 2011 The reduced expressions of MMP-2 and u-PA, as well as inhibition of cell invasion were obtained in the cultures pre-treated with PD98059 (Erk1/2 inhibitor) and SB203580 (p38 inhibitor). SB 203580 160-168 mitogen-activated protein kinase 3 Homo sapiens 138-144 21600278-7 2011 Pretreatment with SB203580, which is a p38 MAPK specific inhibitor, or expression of the dominant negative p38 MAPK (DN p38 MAPK) gene blocked esculetin-induced p38 MAPK activation and p21WAF1 expression. SB 203580 18-26 mitogen-activated protein kinase 3 Homo sapiens 43-47 21983652-8 2011 Increases in HSP27 phosphorylation were suppressed by pretreating cells with SB203580 or SP600125, which are inhibitors of p38 MAPK or JNK, respectively. SB 203580 77-85 mitogen-activated protein kinase 3 Homo sapiens 127-131 21325823-8 2011 The further study indicated that losartan, NAC, MEK1/2 inhibitor PD98059, p38MAPK inhibitor SB203580 obviously inhibited ERK1/2 and p38MAPK phosphorylation, and PD98059, SB203580 and NF-kappaB inhibitor PDTC reduced Ang II -induced mRNA and protein expression of CRP in U937 macrophages. SB 203580 92-100 mitogen-activated protein kinase 3 Homo sapiens 121-127 21257914-5 2011 The MAPK p38 inhibitor SB-203580 significantly inhibited TF expression induced by mechanical and chemical stimulations, but the MEK inhibitor PD-98059 did not inhibit TF induced by TFF. SB 203580 23-32 mitogen-activated protein kinase 3 Homo sapiens 4-8 21317307-6 2011 In contrast, pretreatment with P38 MAPK inhibitor SB203580 resulted in upregulation of atorvastatin + LPS-induced ERK1/2 phosphorylation but had no significant effects on NF-kappaB activity. SB 203580 50-58 mitogen-activated protein kinase 3 Homo sapiens 114-120 21237253-6 2011 Further study showed that both PDTC, a NF-kappaB inhibitor, and SB203580, a p38MAPK inhibitor, could abolish the repression of HCE1 and HCE2 mediated by LPS, but U0126, a selective ERK1/2 inhibitor, could not do so, suggesting the repression of HCE1 and HCE2 by LPS through the p38MAPK-NF-kappaB pathway. SB 203580 64-72 mitogen-activated protein kinase 3 Homo sapiens 181-187 21177635-8 2011 ERK1/2 pathway inhibitor, UO126, failed IL-8 promoter activity, whereas p38 MAPK inhibitor, SB203580, decreased the stabilization of IL-8 messenger RNA following V. parahaemolyticus infection. SB 203580 92-100 mitogen-activated protein kinase 3 Homo sapiens 76-80 21082355-11 2011 MAP kinase inhibitors SB203580, SP600125 and PD98059 confirm the role of p38 MAPK and JNK in OA induced caspase-3 activation and cell death. SB 203580 22-30 mitogen-activated protein kinase 3 Homo sapiens 77-81 21853067-6 2011 Obviously, the induction of autophagic vacuole formation by SB203580 and SB202190 is due to off-target effects of these inhibitors on post-translational protein modifications, such as phosphorylation of the MAPKs ERK1/2 and JNK1/2, ribosomal protein S6, and PKB/Akt. SB 203580 60-68 mitogen-activated protein kinase 3 Homo sapiens 213-219 22174924-7 2011 ERK1/2 pathway and P38 pathway were inhibited with the specific inhibitors PD98059 and SB203580. SB 203580 87-95 mitogen-activated protein kinase 3 Homo sapiens 0-6 19397700-7 2009 The p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 diminished Ang II-induced Smad2 phosphorylation. SB 203580 58-66 mitogen-activated protein kinase 3 Homo sapiens 42-46 20034375-9 2009 Phosphorylation of ERK1/2, and the gene expression of Has2, Tnfaip6 and Ptgs2 were also suppressed by H89, SB203580 and U0126, however, these negative effects were overcome by the addition of EGF to the medium, but not in the U0126 treatment group. SB 203580 107-115 mitogen-activated protein kinase 3 Homo sapiens 19-25 19651223-7 2009 HaCaT cells cultured with CGRP had a significant increase in phosphorylated ERK1/2, p38 and JNK, and CGRP induced DNA synthesis was inhibited by PD 98059 or SB 203580, selective inhibitors of MAP kinase kinase (MEK, which is upstream from ERK) and p38, respectively. SB 203580 157-166 mitogen-activated protein kinase 3 Homo sapiens 76-82 20627382-8 2010 In addition, VIP treatment induced rapid phosphorylation of ERK1/2 and p38MAPK, and PD98059 and SB203580 were able to inhibit VIP-induced phosphorylation of ERK1/2 and p38MAPK, respectively. SB 203580 96-104 mitogen-activated protein kinase 3 Homo sapiens 157-163 20562007-6 2010 Of physiological significance, in agreement with the mitogenic role of the MAPK cascade, ATP increased Caco-2 cell proliferation, and this effect was blocked by UO126, SB203580 and SP600125, the specific inhibitors of ERK1/2, p38 MAPK and JNK1/2, respectively. SB 203580 168-176 mitogen-activated protein kinase 3 Homo sapiens 75-79 20562007-6 2010 Of physiological significance, in agreement with the mitogenic role of the MAPK cascade, ATP increased Caco-2 cell proliferation, and this effect was blocked by UO126, SB203580 and SP600125, the specific inhibitors of ERK1/2, p38 MAPK and JNK1/2, respectively. SB 203580 168-176 mitogen-activated protein kinase 3 Homo sapiens 218-224 19961386-11 2009 The activation of ERK1/2 and p38 induced by H2S was inhibited by the specific inhibitor of MAPK/ERK kinase ([MEK]; U0126) or p38 (SB203580). SB 203580 130-138 mitogen-activated protein kinase 3 Homo sapiens 18-24 19961386-11 2009 The activation of ERK1/2 and p38 induced by H2S was inhibited by the specific inhibitor of MAPK/ERK kinase ([MEK]; U0126) or p38 (SB203580). SB 203580 130-138 mitogen-activated protein kinase 3 Homo sapiens 18-21 18552392-11 2008 Pretreatment of cells with SB203580, an inhibitor for p38MAP kinase, reduced the H(2)O(2)- and TGF-beta2-stimulated Hsp27 expression, whereas pretreatment with PD98059 and U0126, specific inhibitors of ERK1/2, and SP600125, a specific c-Jun N-terminal kinase inhibitor, had no effects. SB 203580 27-35 mitogen-activated protein kinase 3 Homo sapiens 202-208 19013215-5 2009 In concomitant with the elevation of intracellular ROS formation, BH4-induced activation of MAPK, p38 and ERK1/2 in SH-SY5Y cells is attenuated by pretreatment with MAPK inhibitors, SB203580 or PD98059. SB 203580 182-190 mitogen-activated protein kinase 3 Homo sapiens 106-112 18710428-6 2009 Inhibition studies using SB203580 (inhibitor of p38MAPK), U0126 (inhibitor of mitogen-activated or extracellular signal-regulated protein kinase 1/2) and MG132 (inhibitor of NF-kappaB) showed that the phosphorylation of Erk1/2 and p38MAPK with activation of NF-kappaB was closely related to MMP-9 upregulation in both cell lines. SB 203580 25-33 mitogen-activated protein kinase 3 Homo sapiens 220-226 18778461-9 2008 This increase was antagonized by; (1) PKC inhibitors (10 microM bisindolylmaleimide I and 10 microM Ro-32-0432), and (2) inhibitors of the p38, extracellular signal related kinases 1 and 2 (ERK1/2) and C-jun terminal kinase (JNK) MAPK pathways (10 microM SB203580, 10 microM PD98059 and 10 microM SP600125, respectively). SB 203580 255-263 mitogen-activated protein kinase 3 Homo sapiens 144-188 18373739-5 2008 For the evaluation of the role of MAPKs, PD98059, SP600125 and SB203580 were used as MAPKs inhibitors for ERK1/2, JNK1/2 and p38 MAPK, respectively. SB 203580 63-71 mitogen-activated protein kinase 3 Homo sapiens 106-112 18358890-4 2008 LPS-stimulated translocation of nuclear factor kappa B (NF-kappaB) into the nucleus, which was blocked by inhibitors of amino kinase terminal (AKT, LY294002), extracellular signal regulated kinase 1/2 (ERK 1/2, PD98059), p38 (SB203580), and c-jun NH2-terminal kinase (JNK, SP600125) or terrein. SB 203580 226-234 mitogen-activated protein kinase 3 Homo sapiens 202-209 18495191-8 2008 A pre-treatment with p38 MAPK inhibitor (SB203580) suppressed Erk1/2 inhibition induced by DNCB or thimerosal demonstrating a direct interaction between p38 MAPK and Erk1/2. SB 203580 41-49 mitogen-activated protein kinase 3 Homo sapiens 62-68 18495191-8 2008 A pre-treatment with p38 MAPK inhibitor (SB203580) suppressed Erk1/2 inhibition induced by DNCB or thimerosal demonstrating a direct interaction between p38 MAPK and Erk1/2. SB 203580 41-49 mitogen-activated protein kinase 3 Homo sapiens 25-29 18495191-8 2008 A pre-treatment with p38 MAPK inhibitor (SB203580) suppressed Erk1/2 inhibition induced by DNCB or thimerosal demonstrating a direct interaction between p38 MAPK and Erk1/2. SB 203580 41-49 mitogen-activated protein kinase 3 Homo sapiens 166-172 18288130-7 2008 Further evidence is provided that PD98059 or SB203580 inhibited hNUDC- or TPO-induced cell proliferation and differentiation, suggesting that ERK1/2 and p38 MAPK pathways are necessary in megakaryocyte development. SB 203580 45-53 mitogen-activated protein kinase 3 Homo sapiens 142-148 18288130-7 2008 Further evidence is provided that PD98059 or SB203580 inhibited hNUDC- or TPO-induced cell proliferation and differentiation, suggesting that ERK1/2 and p38 MAPK pathways are necessary in megakaryocyte development. SB 203580 45-53 mitogen-activated protein kinase 3 Homo sapiens 157-161 18074350-7 2008 Consistent with this, p38 MAPK inhibitors such as SB203580 and SB202190 also synergistically enhance the cytotoxicity of CA4 in cells where p38 MAPK is activated by CA4. SB 203580 50-58 mitogen-activated protein kinase 3 Homo sapiens 26-30 18639962-11 2008 Inhibition of ERK1/2, JNK1/2 and p38 MAPK with PD98059, SP600125 and SB203580, respectively, led to the suppression of the shear stress-induced IL-8 gene expression (P<0.01), which was also blocked by JNK1/2 siRNA (small interfering RNA) (P<0.01). SB 203580 69-77 mitogen-activated protein kinase 3 Homo sapiens 14-20 18361842-12 2008 Suppression ERK1/2 activation by treatment with PD98059 or p38 activation by treatment with SB203580 attenuated the cell-cycle arrest at the G(1) phase respectively. SB 203580 92-100 mitogen-activated protein kinase 3 Homo sapiens 12-18 18639962-11 2008 Inhibition of ERK1/2, JNK1/2 and p38 MAPK with PD98059, SP600125 and SB203580, respectively, led to the suppression of the shear stress-induced IL-8 gene expression (P<0.01), which was also blocked by JNK1/2 siRNA (small interfering RNA) (P<0.01). SB 203580 69-77 mitogen-activated protein kinase 3 Homo sapiens 37-41 17689939-6 2007 In contrast, SB203580, a p38 MAPK pathway blocker, blocked RSVL-induced p38 phosphorylation, but resulted in an increase of cell proliferation and a more osteoblastic maturation. SB 203580 13-21 mitogen-activated protein kinase 3 Homo sapiens 29-33 17959047-7 2007 Three chemical inhibitors of MAPK (AG126, SP600125 and SB203580) could significantly inhibit the cell cycle alteration because of BaP treatment. SB 203580 55-63 mitogen-activated protein kinase 3 Homo sapiens 29-33 17940558-7 2007 (3) The upregulation effect of ProMMP-7 was partially blocked after incubation of ERK1/2 inhibitors PD98059 and P38 inhibitors SB203580 prior to FVIIa, The expression of ProMMP-7 decreased by 32%+/-5% and 61%+/-10% respectively (P<0.05).whereas JNK inhibitors SP600125 did not have the effect. SB 203580 127-135 mitogen-activated protein kinase 3 Homo sapiens 82-88 17591797-2 2007 A p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, blocked elevation of COX-2 mRNA levels, whereas PD98059, which blocks the Erk1/2 cascade, partially suppressed the increase. SB 203580 57-65 mitogen-activated protein kinase 3 Homo sapiens 40-44 17975262-6 2007 Furthermore, SB203580 and PD098059 act as inhibitors of p38MAPK and ERK1/2 respectively, wortmannin, an inhibitor of phosphatidylinositol-3-kinase, and cyclosporin A, a calcineurin inhibitor, hindered both translocation of Rac2 from the cytosol to the plasma membrane and enhancement of Rac2 GTP-binding elicited by Ang II. SB 203580 13-21 mitogen-activated protein kinase 3 Homo sapiens 68-74 17519236-10 2007 IGFBP-6-induced cell migration was inhibited by SB203580, an inhibitor of p38 MAPK, and PD98059, an inhibitor of ERK1/2 MAPK activation. SB 203580 48-56 mitogen-activated protein kinase 3 Homo sapiens 78-82 17234706-8 2007 SB203580 (a specific inhibitor of p38 MAPK) alone did not affect cellular apoptosis; however, it abolished palmitate-induced apoptosis and p38 MAPK activation. SB 203580 0-8 mitogen-activated protein kinase 3 Homo sapiens 38-42 17457842-5 2007 Additionally, MAPK pathway activities were studied using the PD98059 (an ERK inhibitor), SB203580 (a p38 kinase inhibitor), and SP600125 (a JNK inhibitor), to determine the role in keloid following PDL treatment. SB 203580 89-97 mitogen-activated protein kinase 3 Homo sapiens 14-18 17065399-6 2006 Incubation with SB203580 resulted in a decrease in phosphorylated p38 MAPK and a concomitant increase in the phosphorylation of ERK1/2. SB 203580 16-24 mitogen-activated protein kinase 3 Homo sapiens 128-134 17251521-6 2007 PD-98059, SB-203580, SP-600125, and PDTC-which are inhibitors of ERK1/2, p38, JNK, and nuclear factor-kappaB (NF-kappaB), respectively-attenuated the IL-1alpha-induced COX-2 mRNA expression and activated protein kinase C PGE(2) secretion. SB 203580 10-19 mitogen-activated protein kinase 3 Homo sapiens 65-71 17306932-9 2007 After inhibition of p38 and ERK1/2 with SB203580 or PD98059, only the inhibition of the p38 pathway had an inhibitory effect on MMP-2 gelatinolytic activity. SB 203580 40-48 mitogen-activated protein kinase 3 Homo sapiens 28-34 17374178-10 2007 Inhibition of ERKs activation by AG126, AP-1 by curcumin, and JNKs by SP600125 could reduced the induction of cyclin D1 and CDK4, whereas inhibition of p38K by SB203580 did not show any inhibitory effects on S-HELF. SB 203580 160-168 mitogen-activated protein kinase 3 Homo sapiens 14-18 16924420-6 2006 SB203580, a specific p38 MAPK inhibitor, reduced phosphorylation of Smad3, while it slightly enhanced phosphorylation of Smad2. SB 203580 0-8 mitogen-activated protein kinase 3 Homo sapiens 25-29 17065399-7 2006 Phosphorylation of ERK1/2 was augmented by co-incubation of MH with SB203580. SB 203580 68-76 mitogen-activated protein kinase 3 Homo sapiens 19-25 16564547-6 2006 Inhibition of ERK1/2, p38 kinase, and JNK pathways was performed with PD98059, SB203580, and SP600125, respectively. SB 203580 79-87 mitogen-activated protein kinase 3 Homo sapiens 14-20 16814101-6 2006 Furthermore, it seems that p38(SAPK) is upstream of ERK1/2 and Akt1, since a p38(SAPK) inhibitor SB203580 significantly blocked H2O2-induced activation of ERK1/2 and Akt1. SB 203580 97-105 mitogen-activated protein kinase 3 Homo sapiens 52-58 16814101-6 2006 Furthermore, it seems that p38(SAPK) is upstream of ERK1/2 and Akt1, since a p38(SAPK) inhibitor SB203580 significantly blocked H2O2-induced activation of ERK1/2 and Akt1. SB 203580 97-105 mitogen-activated protein kinase 3 Homo sapiens 155-161 15713910-7 2005 The p38 mitogen-activated protein kinase (MAPK) inhibitor SB-203580 but not the extracellular signal-regulated kinase 1/2 inhibitor (PD-98059) nor the protein kinase C inhibitor (calphostin) blunted ICAM-1 expression and mononuclear cell adhesion to the monolayer. SB 203580 58-67 mitogen-activated protein kinase 3 Homo sapiens 42-46 16761312-5 2006 sPLA(2) induced the phosphorylation of the MAPK p38 and ERK1/2, and inhibition of these kinases by SB203580 and PD98059, respectively, reduced TNF-alpha and CXCL8 release. SB 203580 99-107 mitogen-activated protein kinase 3 Homo sapiens 43-47 16257255-3 2006 This action could be mediated by mitogen-activated protein kinase/extracellular signal regulated kinase 1/2 (MAPK/ERK1/2) and MAPK/p38 because their activation could be distinctly blocked by MAPK inhibitors, PD098059 or SB203580. SB 203580 220-228 mitogen-activated protein kinase 3 Homo sapiens 114-120 16343928-5 2005 Pretreatment of MAPK inhibitors (PD98059 and SB203580) markedly blocked Ca(2+)-induced IL-8 production from cells, and anti-inflammatory drugs, such as dexamethasone and cyclosporin A, partially inhibited the activation of ERK1/2. SB 203580 45-53 mitogen-activated protein kinase 3 Homo sapiens 223-229 16187236-7 2005 The mitogen activated protein kinase (MAPK), p38, was also activated by IGF-I and inhibition of p38 by SB203580 blocked IGF-I induced cell motility. SB 203580 103-111 mitogen-activated protein kinase 3 Homo sapiens 38-42 16573830-7 2006 The effects of heterodimeric S100A8/S100A9 were reduced by inhibition of the MAP-kinase pathways ERK1/2 and p38 by PD 98059 and SB 203580, respectively. SB 203580 128-137 mitogen-activated protein kinase 3 Homo sapiens 97-103 16391519-7 2005 Extracellular signaling-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) were activated during phagocytosis of SOZ, and Tat-C3 and SB203580 reduced ERK1/2 and p38 MAPK activation, suggesting that RhoA and p38 MAPK may be upstream regulators of ERK1/2. SB 203580 156-164 mitogen-activated protein kinase 3 Homo sapiens 0-49 16391519-7 2005 Extracellular signaling-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) were activated during phagocytosis of SOZ, and Tat-C3 and SB203580 reduced ERK1/2 and p38 MAPK activation, suggesting that RhoA and p38 MAPK may be upstream regulators of ERK1/2. SB 203580 156-164 mitogen-activated protein kinase 3 Homo sapiens 92-96 16391519-7 2005 Extracellular signaling-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) were activated during phagocytosis of SOZ, and Tat-C3 and SB203580 reduced ERK1/2 and p38 MAPK activation, suggesting that RhoA and p38 MAPK may be upstream regulators of ERK1/2. SB 203580 156-164 mitogen-activated protein kinase 3 Homo sapiens 173-179 16391519-7 2005 Extracellular signaling-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) were activated during phagocytosis of SOZ, and Tat-C3 and SB203580 reduced ERK1/2 and p38 MAPK activation, suggesting that RhoA and p38 MAPK may be upstream regulators of ERK1/2. SB 203580 156-164 mitogen-activated protein kinase 3 Homo sapiens 269-275 16211253-6 2005 Inhibiting p38MAPK and ERK1/2 with the p38MAPK inhibitors (SB203580 and SB202190) and the MEK1/2 inhibitor (PD98059 and U0126) or with expression of dominant negative p38MAPK and ERK1/2 abolished SR-induced HSP72 synthesis and HSP70 promoter-driven CAT activity. SB 203580 59-67 mitogen-activated protein kinase 3 Homo sapiens 23-29 15194004-4 2004 Inhibition of activated/phosphorylated mitogen-activated protein kinase (MAPK) with phospho-p38 or phospho-p42/44 specific inhibitors, SB203580 or U0126, induces apoptosis without DADS treatment, indicating that at least the endogenous activated forms of p38 MAPK and p42/p44 MAPK markedly exert cytoprotective roles from cell apoptosis in the HepG2 hepatoma cells. SB 203580 135-143 mitogen-activated protein kinase 3 Homo sapiens 73-77 15874933-7 2005 The ERK1/2 and p38 MAPK inhibitors PD98059 (PD) and SB203580 (SB) blocked cell proliferation, but only PD blocked cell migration. SB 203580 52-60 mitogen-activated protein kinase 3 Homo sapiens 4-10 15874933-7 2005 The ERK1/2 and p38 MAPK inhibitors PD98059 (PD) and SB203580 (SB) blocked cell proliferation, but only PD blocked cell migration. SB 203580 52-60 mitogen-activated protein kinase 3 Homo sapiens 19-23 15777650-7 2005 In fact, by using the specific inhibitors SB203580 (specific for p38 MAPK) and PD98059 (specific for ERK-1/2 MAPK), we found that ERK-1/2, but not p38, play a major role in Runx2 activation. SB 203580 42-50 mitogen-activated protein kinase 3 Homo sapiens 130-137 15863359-4 2005 PAF synthesis induced by extracellular pH 5.4 correlated with the activation of a stress-activated kinase, p38 mitogen-activated protein kinase (MAPK), and was blocked by the p38 MAPK inhibitor SB 203580. SB 203580 194-203 mitogen-activated protein kinase 3 Homo sapiens 145-149 15757638-5 2005 The addition of SB203580, an inhibitor of p38 MAPK, suppressed the increase in the phosphorylation of ERK1/2 after the change to LK medium. SB 203580 16-24 mitogen-activated protein kinase 3 Homo sapiens 102-108 15345332-6 2004 Furthermore, both SB203580 (an inhibitor of p38 mitogen-activated protein kinase [MAPK]) and PD98059 (an inhibitor of MEK, upstream of ERK) attenuated the BK-induced IL-6 and PGE(2) synthesis. SB 203580 18-26 mitogen-activated protein kinase 3 Homo sapiens 82-86 15336911-9 2004 In accordance with the different potency of TNF-alpha in activating ERK1/2 and p38 MAPK, the TNF-alpha-induced oxidative responses were more sensitive to the inhibitory effects of SB203580 than to those of PD98059 in young as well as elderly subjects. SB 203580 180-188 mitogen-activated protein kinase 3 Homo sapiens 68-74 15207247-3 2004 In this report, we demonstrate, using two potent and selective inhibitors of MEK activation by Raf-1 (PD-098059) and p38 (SB-203580), that both ERK1/2 and p38 pathways play a key role in the production of IL-8 by porins and LPS. SB 203580 122-131 mitogen-activated protein kinase 3 Homo sapiens 144-150 14742313-6 2004 Additionally, the treatment of inhibitors of MEK (PD98059) and p38 (SB203580) to DU145 cells resulted in the reduction of FCM-induced phosphorylation of ERK1/2 and p38 concomitantly marked reduction in MMP-2 and -9 expressions. SB 203580 68-76 mitogen-activated protein kinase 3 Homo sapiens 153-159 15218990-3 2004 IL-8 production was dependent on phosphorylation of ERK-1 and -2 and p38 MAPK, as examined by PD 098059 (10 microM), an inhibitor of the upstream activator of MAPK kinase (MKK)-1, and SB 203580 (10 microM), an inhibitor of p38 MAPK. SB 203580 184-193 mitogen-activated protein kinase 3 Homo sapiens 52-64 15047712-7 2004 Inhibition of the MAPK pathway using the pharmacological inhibitors PD98059, U0126, and SB203580 in T98G LGI1-null cells inhibits MMP1 and MMP3 production in an ERK1/2-dependent manner. SB 203580 88-96 mitogen-activated protein kinase 3 Homo sapiens 18-22 15047712-7 2004 Inhibition of the MAPK pathway using the pharmacological inhibitors PD98059, U0126, and SB203580 in T98G LGI1-null cells inhibits MMP1 and MMP3 production in an ERK1/2-dependent manner. SB 203580 88-96 mitogen-activated protein kinase 3 Homo sapiens 161-167 12689930-6 2003 PlGF-mediated cytochemokine mRNA and protein expression was inhibited by PD98059 and wortmannin, inhibitors of mitogen-activated protein kinase kinase (MAPK/MEK) kinase and phosphatidylinositol-3 (PI3) kinase, respectively, but not by SB203580, a p38 kinase inhibitor. SB 203580 235-243 mitogen-activated protein kinase 3 Homo sapiens 152-156 15132853-9 2004 Pretreatment with 10 micro mol/L p38 inhibitor SB203580 antagonized the effect of ATP-induced additional growth inhibition, suggesting that ERK1/2 and p38 pathways play an important role in ATP-induced growth inhibition. SB 203580 47-55 mitogen-activated protein kinase 3 Homo sapiens 140-146 15132853-13 2004 Treatment with ATP could restore their invasive ability, and this effect by ATP could be blocked by pretreatment with SB203580, indicating the involvement of both ERK1/2 and p38 pathways in invasive ability of prostatic cancer cells. SB 203580 118-126 mitogen-activated protein kinase 3 Homo sapiens 163-169 14722101-10 2004 The involvement of ERK1/2 and p38 MAP kinase in acetaldehyde-induced apoptosis was confirmed by selective kinase inhibitors U0126, SB203580, and SB202190. SB 203580 131-139 mitogen-activated protein kinase 3 Homo sapiens 19-25 14613890-9 2004 In addition, the inhibitors of the MAPK pathway, SB-203580 and U-0126, inhibited nucleotide-induced elastase release. SB 203580 49-58 mitogen-activated protein kinase 3 Homo sapiens 35-39 14556662-10 2003 p38 MAPK inhibitors, SB203580 and FR167653, dose-dependently enhanced EA-induced cell death. SB 203580 21-29 mitogen-activated protein kinase 3 Homo sapiens 4-8 12618272-9 2003 ERK1/2 and p38 MAPK were phosphorylated by HGF and a MEK inhibitor PD98059 and a p38 MAPK inhibitor SB203580 inhibited HGF-stimulated HUVEC growth by 66% and by 58%; however, HGF-induced phosphorylation of ERK1/2 and p38 MAPK was not inhibited by L-NAME, indicating that NO is not an upstream activator of ERK1/2 and p38 MAPK. SB 203580 100-108 mitogen-activated protein kinase 3 Homo sapiens 206-212 12663671-3 2003 Interruption of p38 and ERK1/2 signaling pathways by pretreatment with inhibitors SB203580 and PD98059 and subsequent stimulation with HGF or KGF abolished the activation and nuclear localization. SB 203580 82-90 mitogen-activated protein kinase 3 Homo sapiens 24-30 12763029-5 2003 Pretreatment with the p38 MAPK inhibitors SB203580 (10 microM) (SB) or SKF-86002 (10 microM) (SKF) potently inhibited AngII-induced p38 MAPK activation, but enhanced AngII-mediated ERK1/2 activation. SB 203580 42-50 mitogen-activated protein kinase 3 Homo sapiens 26-30 12763029-5 2003 Pretreatment with the p38 MAPK inhibitors SB203580 (10 microM) (SB) or SKF-86002 (10 microM) (SKF) potently inhibited AngII-induced p38 MAPK activation, but enhanced AngII-mediated ERK1/2 activation. SB 203580 42-50 mitogen-activated protein kinase 3 Homo sapiens 136-140 12763029-5 2003 Pretreatment with the p38 MAPK inhibitors SB203580 (10 microM) (SB) or SKF-86002 (10 microM) (SKF) potently inhibited AngII-induced p38 MAPK activation, but enhanced AngII-mediated ERK1/2 activation. SB 203580 42-50 mitogen-activated protein kinase 3 Homo sapiens 181-187 12637634-11 2003 The addition of PD98059 and SB203580, which blocked the activation of ERK1/2 and p38(HOG), respectively, suppressed the TGF-beta-induced collagen alpha1(I) mRNA expression. SB 203580 28-36 mitogen-activated protein kinase 3 Homo sapiens 70-76 12594059-8 2003 Blocking ERK1/2 with PD98059 or p38 MAPK with SB203580 reduced BK-induced IL-6 expression. SB 203580 46-54 mitogen-activated protein kinase 3 Homo sapiens 9-15 12618272-9 2003 ERK1/2 and p38 MAPK were phosphorylated by HGF and a MEK inhibitor PD98059 and a p38 MAPK inhibitor SB203580 inhibited HGF-stimulated HUVEC growth by 66% and by 58%; however, HGF-induced phosphorylation of ERK1/2 and p38 MAPK was not inhibited by L-NAME, indicating that NO is not an upstream activator of ERK1/2 and p38 MAPK. SB 203580 100-108 mitogen-activated protein kinase 3 Homo sapiens 0-6 12704121-8 2003 Moreover, using selective inhibitors for MAP kinase kinase (PD98059) and p38 (SB203580), we show that ERK1/2 exhibited differential effects on production of TNF-alpha and IL-12 p40 by human monocytes, whereas MPL-induced activation of p38 appeared to be predominantly involved in production of IL-10 and IL-12 p40 by MPL-stimulated monocytes. SB 203580 78-86 mitogen-activated protein kinase 3 Homo sapiens 102-108 12667793-10 2003 ICAM-1 mRNA upregulation was inhibited upon incubation with several chemicals, namely, the ERK1/2 inhibitors PD98059 and AG1288 (by 98 and 67%, respectively), of the p38/MAPK pathway SB203580 (by 50%), of the JNK pathway dimethylaminopurine (by 83%), and of the NF-kappaB parthenolide (by 96%). SB 203580 183-191 mitogen-activated protein kinase 3 Homo sapiens 91-97 12618272-9 2003 ERK1/2 and p38 MAPK were phosphorylated by HGF and a MEK inhibitor PD98059 and a p38 MAPK inhibitor SB203580 inhibited HGF-stimulated HUVEC growth by 66% and by 58%; however, HGF-induced phosphorylation of ERK1/2 and p38 MAPK was not inhibited by L-NAME, indicating that NO is not an upstream activator of ERK1/2 and p38 MAPK. SB 203580 100-108 mitogen-activated protein kinase 3 Homo sapiens 206-212 12388073-5 2002 Pharmacological analysis of signaling pathways revealed that the inhibition of cAMP-driven epithelial Cl(-) secretion by TGF-beta was blocked by pretreatment with SB-203580, a specific inhibitor of p38 MAPK, but not by inhibitors of JNK, ERK1/2 MAPK, or phosphatidylinositol 3"-kinase. SB 203580 163-172 mitogen-activated protein kinase 3 Homo sapiens 238-244 12391274-7 2002 Cells activated by IL-1beta showed increased extracellular signal-regulated kinase (ERK)1/2 and p38 phosphorylation, and IL-1beta-induced MUC2 and MUC5AC production was blocked by the ERK pathway inhibitor PD98059 or the p38 inhibitor SB203580. SB 203580 235-243 mitogen-activated protein kinase 3 Homo sapiens 84-87 12464556-10 2002 ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC(50) of 0.34 microM for IL-1beta production and 0.26 microM for TNFalpha synthesis.p38-MAP kinase inhibitor SB 203580 inhibits IL-1beta- and TNF-alpha-synthesis (IC(50)sof 0.052 microM and 0.46 microM) in the same degree as p38-MAP kinase activity (IC(50): 0.34 microM). SB 203580 166-175 mitogen-activated protein kinase 3 Homo sapiens 0-4 11910351-6 2002 The MAPK inhibitors, PD098059 for MAP or extracellular signal-regulated kinase 1, SB203580 for p38, and BAY 37-9751 for Raf-1, blocked COX-2 induction by bile acids. SB 203580 82-90 mitogen-activated protein kinase 3 Homo sapiens 4-8 12134900-2 2002 In the present study, by assessing the effect of a specific p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, on the secretion of MMPs and in vitro invasion of various glioma cells, the authors attempt to define the role of the p38 MAPK pathway in the regulation of MMPs and tissue inhibitors of metalloproteinases (TIMPs) activated by phorbol ester (phorbol-12-myristate-13-acetate [PMA]) in the D54 human glioblastoma cell line. SB 203580 115-123 mitogen-activated protein kinase 3 Homo sapiens 98-102 12020969-4 2002 Treatment with SB203580, a specific inhibitor of p38 mitogen-activated protein kinases (MAPK), potently inhibited IL-1-mediated induction of iNOS and TNFalpha in cultures of human fetal astrocytes. SB 203580 15-23 mitogen-activated protein kinase 3 Homo sapiens 88-92 12200131-5 2002 This effect was completely inhibited in the presence of the pharmacological ERK 1/2 mitogen-activated protein kinase (MAPK) pathway inhibitor PD98059 (30 microM) or the p38 MAPK inhibitor SB203580 (1 microM). SB 203580 188-196 mitogen-activated protein kinase 3 Homo sapiens 76-83 12200131-7 2002 Hypoxia induced a time-dependent activation of ERK 1/2 and p38 MAPK activation in human VSMCs, which were completely abolished by PD98059 or SB203580, respectively. SB 203580 141-149 mitogen-activated protein kinase 3 Homo sapiens 47-54 12149431-5 2002 SB 203580, a specific p38 MAPK inhibitor, blocked anti-IgE-induced secretion of all basophil mediators and reduced not only p38 MAPK, but also extracellular signal-regulated kinases 1 and 2 activity, whereas the MAPK antagonist, PD 098059, did not affect p38 MAPK. SB 203580 0-9 mitogen-activated protein kinase 3 Homo sapiens 143-189 12149431-5 2002 SB 203580, a specific p38 MAPK inhibitor, blocked anti-IgE-induced secretion of all basophil mediators and reduced not only p38 MAPK, but also extracellular signal-regulated kinases 1 and 2 activity, whereas the MAPK antagonist, PD 098059, did not affect p38 MAPK. SB 203580 0-9 mitogen-activated protein kinase 3 Homo sapiens 26-30 11401859-6 2001 SB-203580, a p38 MAP kinase antagonist, inhibited ionomycin-induced activation of the oxidase (68 +/- 8%, P < 0.05) and tyrosine phosphorylation of 105- and 72-kDa proteins; conversely, PD-98059, an inhibitor of MAP/extracellular signal-related kinase 1, had no effect. SB 203580 0-9 mitogen-activated protein kinase 3 Homo sapiens 219-256 11784328-5 2002 On the basis of activator/inhibitor studies applying fetal bovine serum, EGF, PD98059, anisomycin, SB203580, forskolin and wortmannin, it could be demonstrated that in U87 cells the ERK1/2 and potentially SAPK/JNK, but not the p38MAPK/SAPK2, pathway contribute to the radiation-induction of Egr-1 promoter. SB 203580 99-107 mitogen-activated protein kinase 3 Homo sapiens 182-188 11549724-8 2001 Blocking either the ERK1/ERK2 or the p38 pathway (with PD98059 or SB203580, respectively) significantly inhibited Bz-ATP-induced MCP-1 expression. SB 203580 66-74 mitogen-activated protein kinase 3 Homo sapiens 20-24 11690563-7 2001 Inhibition of p38 MAPK activity with p38-specific inhibitor, SB203580, partially inhibited lectin-II-induced DNA fragmentation. SB 203580 61-69 mitogen-activated protein kinase 3 Homo sapiens 18-22 11741826-4 2002 Inhibition of p38 MAPK activity with SB-203580 prevented the increases in both monolayer permeability and MLC-P. SB 203580 37-46 mitogen-activated protein kinase 3 Homo sapiens 18-22 11461121-11 2001 An inhibitor of p38 kinase, SB203580, protected the cells partially from Taxol and, unexpectedly, activated ERK 1/2 kinases. SB 203580 28-36 mitogen-activated protein kinase 3 Homo sapiens 108-115 11425486-6 2001 Curcumin and SB203580, which inhibit JNK and p38 MAPK signaling pathways, but not herbimycin A/staurosporine, prevented the MGO-induced PARP degradation. SB 203580 13-21 mitogen-activated protein kinase 3 Homo sapiens 49-53 11339820-11 2001 Inhibition of p38 MAPK pathway by SB 203580 increased both ERK1/2 phosphorylation and cell proliferation demonstrating that the inhibitor can either directly or indirectly activate the ERK1/2 MAPK pathway. SB 203580 34-43 mitogen-activated protein kinase 3 Homo sapiens 59-65 11339820-11 2001 Inhibition of p38 MAPK pathway by SB 203580 increased both ERK1/2 phosphorylation and cell proliferation demonstrating that the inhibitor can either directly or indirectly activate the ERK1/2 MAPK pathway. SB 203580 34-43 mitogen-activated protein kinase 3 Homo sapiens 185-191 11339820-11 2001 Inhibition of p38 MAPK pathway by SB 203580 increased both ERK1/2 phosphorylation and cell proliferation demonstrating that the inhibitor can either directly or indirectly activate the ERK1/2 MAPK pathway. SB 203580 34-43 mitogen-activated protein kinase 3 Homo sapiens 18-22 11226388-7 2001 Furthermore, adenosine A(1) receptor-mediated increases in p42/p44 MAPK were sensitive to the MAPK kinase 1 inhibitor PD 98059 (2"-amino-3"-methoxyflavone), whereas p38 MAPK responses were blocked by the p38 MAPK inhibitor SB 203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole). SB 203580 223-232 mitogen-activated protein kinase 3 Homo sapiens 67-71 11226388-7 2001 Furthermore, adenosine A(1) receptor-mediated increases in p42/p44 MAPK were sensitive to the MAPK kinase 1 inhibitor PD 98059 (2"-amino-3"-methoxyflavone), whereas p38 MAPK responses were blocked by the p38 MAPK inhibitor SB 203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole). SB 203580 234-305 mitogen-activated protein kinase 3 Homo sapiens 67-71 11806247-8 2001 SB203580, a specific P38 MAPK inhibitor, blocked the ability of IL-1 beta to induce VEGF mRNA and promoter activity. SB 203580 0-8 mitogen-activated protein kinase 3 Homo sapiens 25-29 10510396-5 1999 However, we demonstrate that SB 203580 at concentrations >/=10 microM can also inhibit activation of ERK-1/2 in neutrophils. SB 203580 29-38 mitogen-activated protein kinase 3 Homo sapiens 104-111 10903731-6 2000 The cytolytic activity of NK92 against K562 target cells, which was augmented in a dose-dependent manner by IL-18 in the presence of trace amounts of IL-2, was suppressed by the specific inhibitors of MAPK pathways (PD098059 and SB203580). SB 203580 229-237 mitogen-activated protein kinase 3 Homo sapiens 201-205 10845922-6 2000 On the other hand, inhibition of p38 by SB203580 indicates that this MAPK is involved in the control of IL-1beta production at both transcriptional and translational levels. SB 203580 40-48 mitogen-activated protein kinase 3 Homo sapiens 69-73 10625698-6 2000 Contraction-stimulated phosphorylation of ERK1/2 and p38(MAPK) was completely inhibited by pretreatment with PD98059 (MAPK kinase inhibitor) and SB203580 (p38(MAPK) inhibitor), respectively. SB 203580 145-153 mitogen-activated protein kinase 3 Homo sapiens 42-48 10960075-0 2000 The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. SB 203580 29-37 mitogen-activated protein kinase 3 Homo sapiens 129-132 10960075-6 2000 Overexpression of kinase-deficient mutants belonging to the ERK1/2, JNK, and p38 pathways showed that only dominant-negative Raf-1 abrogated SB203580-enhanced NF-kappaB activity. SB 203580 141-149 mitogen-activated protein kinase 3 Homo sapiens 60-66 10960075-7 2000 This would implicate the involvement of the ERK1/2 pathway in the enhancing effects of SB203580 on NF-kappaB-mediated gene transcription. SB 203580 87-95 mitogen-activated protein kinase 3 Homo sapiens 44-50 10960075-9 2000 SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-kappaB transcriptional activity. SB 203580 0-8 mitogen-activated protein kinase 3 Homo sapiens 48-51 10625698-8 2000 Use of PD98059 or SB203580 revealed that stimulation of p90(Rsk) and MAPKAP-K2 most closely reflects ERK and p38(MAPK) stimulation, respectively. SB 203580 18-26 mitogen-activated protein kinase 3 Homo sapiens 101-104 9120270-1 1997 The role of p38 mitogen-activated protein kinase (MAPK) in responses of human fibroblasts and vascular endothelial cells to IL-1 was investigated by use of a pyridinyl imidazole compound (SB 203580), which specifically inhibits the enzyme. SB 203580 188-197 mitogen-activated protein kinase 3 Homo sapiens 50-54 10385244-9 1999 The involvement of the kinase signalling pathways was further analysed by using SB203580 and PD98059, specific inhibitors of the p38 and ERK1/2 signalling route. SB 203580 80-88 mitogen-activated protein kinase 3 Homo sapiens 137-143 9923649-6 1998 OA-elicited enhancement of MMP-1 mRNA abundance was also strongly prevented by two chemical MAPK inhibitors: PD 98059, a specific inhibitor of the activation of ERK1,2 kinases MEK1,2; and SB 203580, a selective inhibitor of p38 activity. SB 203580 188-197 mitogen-activated protein kinase 3 Homo sapiens 92-96 9923649-6 1998 OA-elicited enhancement of MMP-1 mRNA abundance was also strongly prevented by two chemical MAPK inhibitors: PD 98059, a specific inhibitor of the activation of ERK1,2 kinases MEK1,2; and SB 203580, a selective inhibitor of p38 activity. SB 203580 188-197 mitogen-activated protein kinase 3 Homo sapiens 161-167 10400419-8 1999 In contrast, PD98059, a specific inhibitor of the ERK pathway, counteracted the suppressive effects of SB203580 and IL-1 on the apoptotic process indicating that the protective effect of SB203580 and IL-1 might be the result of a shift in the balance between the ERK1/2 and p38/JNK route. SB 203580 103-111 mitogen-activated protein kinase 3 Homo sapiens 50-53 10400419-8 1999 In contrast, PD98059, a specific inhibitor of the ERK pathway, counteracted the suppressive effects of SB203580 and IL-1 on the apoptotic process indicating that the protective effect of SB203580 and IL-1 might be the result of a shift in the balance between the ERK1/2 and p38/JNK route. SB 203580 103-111 mitogen-activated protein kinase 3 Homo sapiens 263-269 10400419-8 1999 In contrast, PD98059, a specific inhibitor of the ERK pathway, counteracted the suppressive effects of SB203580 and IL-1 on the apoptotic process indicating that the protective effect of SB203580 and IL-1 might be the result of a shift in the balance between the ERK1/2 and p38/JNK route. SB 203580 187-195 mitogen-activated protein kinase 3 Homo sapiens 50-53 10400419-8 1999 In contrast, PD98059, a specific inhibitor of the ERK pathway, counteracted the suppressive effects of SB203580 and IL-1 on the apoptotic process indicating that the protective effect of SB203580 and IL-1 might be the result of a shift in the balance between the ERK1/2 and p38/JNK route. SB 203580 187-195 mitogen-activated protein kinase 3 Homo sapiens 263-269 9916078-5 1999 By using PD-98059 and SB203580, two potent and selective inhibitors of MEK1 (a kinase upstream of ERK1/2) and p38, respectively, we have demonstrated that both ERK1/2 and p38 cascades play a key role in the production of IL-8 by monocytes and PMN stimulated with bacterial fractions. SB 203580 22-30 mitogen-activated protein kinase 3 Homo sapiens 98-104 9916078-5 1999 By using PD-98059 and SB203580, two potent and selective inhibitors of MEK1 (a kinase upstream of ERK1/2) and p38, respectively, we have demonstrated that both ERK1/2 and p38 cascades play a key role in the production of IL-8 by monocytes and PMN stimulated with bacterial fractions. SB 203580 22-30 mitogen-activated protein kinase 3 Homo sapiens 160-166 9120270-2 1997 SB 203580 inhibited (50% inhibitory concentration approximately 0.5 microM) IL-1-induced phosphorylation of heat shock protein 27 (an indicator of p38 MAPK activity) in fibroblasts without affecting the other known IL-1-activated protein kinase pathways (p42/p44 MAPK, p54 MAPK/c-Jun N-terminal kinase and beta-casein kinase). SB 203580 0-9 mitogen-activated protein kinase 3 Homo sapiens 259-267 32924599-6 2021 Furthermore, sustained activation of mitogen-activated protein kinases (MAPKs) ERK1/2 and p38 was observed wherein ERK1/2 (U0126) and p38 (SB203580) inhibitors confirmed crosstalk ERK1/2-Akt and MAPK intrinsic mitochondrial pathways. SB 203580 139-147 mitogen-activated protein kinase 3 Homo sapiens 79-85 34716498-7 2021 Moverover, CD95 stimulation induced the phosphorylation of p38 and Erk1/2 and Th17 cell differentiation, and p38 specific inhibitor SB203580 or Erk1/2 specific inhibitor PD98059 could induce opposite changes. SB 203580 132-140 mitogen-activated protein kinase 3 Homo sapiens 67-73 35499276-12 2022 MAPK pathway inhibitors (10 muM SB203580 and 10 muM SP600125) could attenuate the NiSO4 -induced increase in apoptosis and inflammation in HUVECs. SB 203580 32-40 mitogen-activated protein kinase 3 Homo sapiens 0-4 33013353-11 2020 Additionally, SB203580, a commercial p38 inhibitor, stimulated STAT3 activation and improved autophagic events rate in breast cancer cells, displaying the role of the MAPK signaling pathway in interplay between apoptosis and autophagy. SB 203580 14-22 mitogen-activated protein kinase 3 Homo sapiens 167-171 30088173-7 2018 Furthermore, inhibiting Erk1/2 by U0126 or p38 by SB203580 partially protected against NO-induced cell death. SB 203580 50-58 mitogen-activated protein kinase 3 Homo sapiens 24-30 32104290-6 2020 In addition, SB203580, a p38 mitogen-activated protein kinase (MAPK)/ERK inhibitor, was used to examine the downstream pathways of CTRP3. SB 203580 13-21 mitogen-activated protein kinase 3 Homo sapiens 63-67 30918168-7 2019 In addition, the BSM hyperresponsiveness to ACh induced by the 24-h incubation with PGD2 was significantly inhibited by co-incubation with SB203580 (a p38 inhibitor), whereas U0126 (a ERK1/2 inhibitor) had no effect on it. SB 203580 139-147 mitogen-activated protein kinase 3 Homo sapiens 184-190 30246289-7 2019 Furthermore, cells treated with the inhibitors of ERK1/2 (PD98059) and p38 (SB203580) mitigated the expression of cytokines induced by LPS, thus suggesting that ERK1/2 and p38 activity are required for the inflammatory response. SB 203580 76-84 mitogen-activated protein kinase 3 Homo sapiens 50-56 30246289-7 2019 Furthermore, cells treated with the inhibitors of ERK1/2 (PD98059) and p38 (SB203580) mitigated the expression of cytokines induced by LPS, thus suggesting that ERK1/2 and p38 activity are required for the inflammatory response. SB 203580 76-84 mitogen-activated protein kinase 3 Homo sapiens 161-167 30461130-7 2019 Furthermore, the inhibitors for NF-kappaB (JSH-23) and mitogen-activated protein kinases (MAPKs) p38 (SB203580) and JNK (SP600125) could also attenuate the effects of SAA1, while the inhibitor for MAPK ERK1/2 (PD 98059) could block the effects of SAA1 only on MMP-1, MMP-8, and LOXL1 but not on MMP-13. SB 203580 102-110 mitogen-activated protein kinase 3 Homo sapiens 202-208 30473635-7 2018 Pre-treatment with the calcitonin receptor-like receptor (CRLR) antagonist CGRP8-37 or a MAPK pathway inhibitor (PD98059, SB203580 or SP600125) completely or partially reversed the pro-proliferative and anti-apoptotic effects and the reduced p-ERK1/2, p-p38 and p-JNK expression induced by CGRP. SB 203580 122-130 mitogen-activated protein kinase 3 Homo sapiens 89-93 29770357-2 2018 Methods: The MAPK pathways (p38, ERK1/2, JNK) were inhibited by SB203580, PD98059, and SP600125 in normal human epidermal keratinocytes (NHEKs), respectively. SB 203580 64-72 mitogen-activated protein kinase 3 Homo sapiens 33-39 30021550-14 2018 Notably, inhibition of p38 MAPK activity by SB203580 decreased rFMW/GFP-induced cleavage of caspase-3 and PARP in THJ-16 T and THJ-29 T cells. SB 203580 44-52 mitogen-activated protein kinase 3 Homo sapiens 27-31 27484511-12 2016 Finally, the employment of NAC and MAPK inhibitors (U0126, SP600125 and SB203580) remarkably blocked the S phase arrest, apoptosis and down-regulation of P-gp induced by Z5. SB 203580 72-80 mitogen-activated protein kinase 3 Homo sapiens 35-39 27829223-6 2016 EGF-induced nuclear co-localization of phospho-Smad2/3 and Snail and cancer cell migration were inhibited by pretreatment with an ERK1/2 inhibitor, PD98059 and a phospho-Smad2 inhibitor, SB203580. SB 203580 187-195 mitogen-activated protein kinase 3 Homo sapiens 130-136 27580989-10 2016 Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin. SB 203580 178-186 mitogen-activated protein kinase 3 Homo sapiens 40-46 27577254-5 2016 Moreover, beta1-AA was also likely to promote proliferation in cardiac fibroblasts through activating p38MAPK and ERK1/2 as p38MAPK inhibitor SB203580 and ERK1/2 inhibitor PD98059 partially reversed the proliferative effect. SB 203580 142-150 mitogen-activated protein kinase 3 Homo sapiens 114-120 27394658-6 2016 p38 and ERK1/2 MAPKs were involved in this effect, as indicated by the Cry1Ac-induced upregulation of CD80 and IL-6 and TNF-alpha abrogation by the p38 MAPK inhibitor SB203580. SB 203580 167-175 mitogen-activated protein kinase 3 Homo sapiens 8-14 25721086-8 2015 However, pretreatments with selective mitogen-activated protein kinase (MAPK) inhibitors, SB203580 (p38 inhibitor) and PD0325901 (ERK1/2 inhibitor), significantly suppressed the activation of EGCG on BTG2 expression. SB 203580 90-98 mitogen-activated protein kinase 3 Homo sapiens 72-76 26879145-9 2016 Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively. SB 203580 63-71 mitogen-activated protein kinase 3 Homo sapiens 201-207 27441000-8 2016 Cotreatment with SB203580 (a p38 inhibitor) and fasudil resulted in the synergistic reduction of MMP-2, MMP-9, and p-p38-MAPK, as well as a reduction in the LPS-stimulated migration capabilities of the RMG cells, suggesting fasudil suppresses the LPS-stimulated migration of RMG cells via directly downregulating the p38-MAPK signaling pathway. SB 203580 17-25 mitogen-activated protein kinase 3 Homo sapiens 121-125 26795953-8 2016 ERK1/2 mitogen activated protein kinase (MAPK) was blocked by PD98059, p38 MAPK by SB203580, and STAT1 by small interference (si) RNA treatment. SB 203580 83-91 mitogen-activated protein kinase 3 Homo sapiens 0-6 26795953-8 2016 ERK1/2 mitogen activated protein kinase (MAPK) was blocked by PD98059, p38 MAPK by SB203580, and STAT1 by small interference (si) RNA treatment. SB 203580 83-91 mitogen-activated protein kinase 3 Homo sapiens 41-45 26795953-8 2016 ERK1/2 mitogen activated protein kinase (MAPK) was blocked by PD98059, p38 MAPK by SB203580, and STAT1 by small interference (si) RNA treatment. SB 203580 83-91 mitogen-activated protein kinase 3 Homo sapiens 75-79 26351820-13 2015 Combined treatment with NaHS and SB203580 (an inhibitor of p38 MAPK) or PD-98059 (an inhibitor of ERK1/2) resulted in the synergistic reduction of COX-2 expression and increase of caspase-3 expression, a decreased number of apoptotic cells, along with decreased cell viability. SB 203580 33-41 mitogen-activated protein kinase 3 Homo sapiens 98-104 25714802-7 2015 Conversely, the p38 MAPK inhibitor SB203580 enhanced cytokine activation of ERK1/2 and the production of MMP-1 similar to that of SB216763. SB 203580 35-43 mitogen-activated protein kinase 3 Homo sapiens 76-82 24081812-6 2014 The MAPK inhibitors PD98059 and SP600125 increased the paracrine to promote tubular formation, while the SB203580 played an opposite role. SB 203580 105-113 mitogen-activated protein kinase 3 Homo sapiens 4-8 25447816-9 2014 Inhibition of ERK1/2/ by PD98059 and p38 by SB203580 inhibited PCA-induced ATF3 expression and transcriptional activation. SB 203580 44-52 mitogen-activated protein kinase 3 Homo sapiens 14-20 24953041-5 2014 Prevention of the phosphorylation of EGFR, ERK1/2, p38 MAPK or MSK1 is by incubating, respectively, with AG1478, PD98059, SB203580 or H89 allowed to elucidate the precise phosphorylation order in the signaling cascade triggered by PGE2: first, EGFR; then, ERK1/2 and p38 MAPK and, finally, MSK1. SB 203580 122-130 mitogen-activated protein kinase 3 Homo sapiens 43-49 24935539-7 2014 The MAPK inhibitor for extracellular signal-regulated kinase 1/2 (U0126) and Jun N-terminal kinase (SP600125) significantly decreased the Biodentine-induced mineralized differentiation of hDPSCs and OCN, DSPP, DMP1, and BSP messenger RNA expression, whereas p38 MAPK inhibitors (SB203580) had no effect. SB 203580 279-287 mitogen-activated protein kinase 3 Homo sapiens 23-64 24331979-6 2014 Moreover, the treatments of PF573228, Y27632 and cytochalasin D promoted p38 and ERK1/2 phosphorylations, and the treatments of U0126 and SB203580 decreased p38 and ERK1/2 phosphorylations, respectively. SB 203580 138-146 mitogen-activated protein kinase 3 Homo sapiens 81-87 24331979-6 2014 Moreover, the treatments of PF573228, Y27632 and cytochalasin D promoted p38 and ERK1/2 phosphorylations, and the treatments of U0126 and SB203580 decreased p38 and ERK1/2 phosphorylations, respectively. SB 203580 138-146 mitogen-activated protein kinase 3 Homo sapiens 165-171 24982891-2 2014 Significant increase of LNCaP cell death (apoptotic and necrotic) and increased levels of active caspase 3 were observed in cells treated with inhibitors of ERK 1/2 (UO126) and p38 (SB203580) prior to IL-1 beta treatment in comparison to cells treated with UO126, SB203580, or IL-1 beta alone. SB 203580 182-190 mitogen-activated protein kinase 3 Homo sapiens 157-164 24451985-9 2014 Furthermore, VEGF significantly stimulated proliferation and migration of pTr cells, but these effects were blocked by SB203580, U0126, rapamycin, and LY294002, which inhibit p38 MAPK, ERK1/2, mTOR, and PI3K, respectively. SB 203580 119-127 mitogen-activated protein kinase 3 Homo sapiens 185-191 24451252-7 2014 A p38 MAPK inhibitor, SB203580, effectively inhibited both spontaneous and LPS- and THP-induced PMN phagocytosis. SB 203580 22-30 mitogen-activated protein kinase 3 Homo sapiens 6-10 23468369-5 2014 Consistently, both nHZ and 15-HETE also promoted phosphorylation of MAPK-activated protein kinase-2, a known p38 MAPK substrate; such an effect was abolished by SB203580, a synthetic p38 MAPK inhibitor. SB 203580 161-169 mitogen-activated protein kinase 3 Homo sapiens 68-72 24452912-8 2014 SB203580, a specific p38 MAPK inhibitor, completely diminished EGCG-induced phosphorylation of p38 and partially blocked EGCG-inhibited OVCAR-3 cell proliferation. SB 203580 0-8 mitogen-activated protein kinase 3 Homo sapiens 25-29 24982891-2 2014 Significant increase of LNCaP cell death (apoptotic and necrotic) and increased levels of active caspase 3 were observed in cells treated with inhibitors of ERK 1/2 (UO126) and p38 (SB203580) prior to IL-1 beta treatment in comparison to cells treated with UO126, SB203580, or IL-1 beta alone. SB 203580 264-272 mitogen-activated protein kinase 3 Homo sapiens 157-164 24015303-5 2013 ET-1 was inhibited by Bosentan, ERK1/2 mitogen activated protein kinase (MAPK) was inhibited by U0126 and p38 MAPK was inhibited by SB203580. SB 203580 132-140 mitogen-activated protein kinase 3 Homo sapiens 32-38 24881958-5 2014 The roles of ERK1/2 and p38 were further confirmed using the ERK1/2 inhibitor (U0126) and p38 inhibitor (SB203580). SB 203580 105-113 mitogen-activated protein kinase 3 Homo sapiens 13-19 24383372-8 2013 ROS generation in response to TGF-beta1, measured as 2,7-dichlorofluorescein-diacetate fluorescence, was inhibited significantly by SB203580 and U0126, implicating both the p38 MAPK and Mekl/2/Erk1/2 signaling pathways. SB 203580 132-140 mitogen-activated protein kinase 3 Homo sapiens 193-199 23697559-4 2013 The phosphorylation of both extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) was markedly upregulated by treating with high amount of HMGB1, while pretreatment with ERK1/2 and p38 MAPK-specific inhibitors (U0126 and SB203580) could attenuate suppression of T cell immune function and nuclear factor of activated T cell (NFAT) activation induced by HMGB1, respectively. SB 203580 262-270 mitogen-activated protein kinase 3 Homo sapiens 211-217 23697559-5 2013 HMGB1-induced activity of ERK1/2 and p38 was not fully inhibited in the presence of U0126 or SB203580. SB 203580 93-101 mitogen-activated protein kinase 3 Homo sapiens 26-32 24060240-6 2013 The 1alpha,25-dihydroxy-22-oxavitamin D3 (Oxa-D3) induced-sCD14 release was inhibited by U0126 (a specific inhibitor of extracellular signal-regulated kinase; ERK1/2) but not by SB203580 (a specific inhibitor of p38 MAPK), and ERK1/2 phosphorylation was accelerated by Oxa-D3. SB 203580 178-186 mitogen-activated protein kinase 3 Homo sapiens 159-165